Please wait a minute...
购物车 申请加入邮件组 English
高级检索 图表检索
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

邮发代号 80-967

2019 Impact Factor: 3.421

热点文章  |  下载排行  |  浏览排行
在线投稿 免费RSS订阅
Frontiers of Medicine  2021, Vol. 15 Issue (5): 718-727   https://doi.org/10.1007/s11684-020-0807-4
  本期目录
Outcomes of haploidentical bone marrow transplantation in patients with severe aplastic anemia-II that progressed from non-severe acquired aplastic anemia
Hongchen Liu1, Xiaoli Zheng2, Chengtao Zhang1, Jiajun Xie1, Beibei Gao1, Jing Shao1,3, Yan Yang1(), Hengxiang Wang2(), Jinsong Yan1()
1. Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Dalian Key Laboratory of Hematology, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian 116027, China
2. Department of Hematology, Air Force Medical Center, PLA, Beijing 100142, China
3. Department of Environmental Health and Toxicology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, School of Public Health, Dalian Medical University, Dalian 116044, China
 全文: PDF(142 KB)   HTML
Abstract：

Severe aplastic anemia II (SAA-II) progresses from non-severe aplastic anemia (NSAA). The unavailability of efficacious treatment has prompted the need for haploidentical bone marrow transplantation (haplo-BMT) in patients lacking a human leukocyte antigen (HLA)-matched donor. This study aimed to investigate the efficacy of haplo-BMT for patients with SAA-II. Twenty-two patients were included and followed up, and FLU/BU/CY/ATG was used as conditioning regimen. Among these patients, 21 were successfully engrafted, 19 of whom survived after haplo-BMT. Four patients experienced grade II–IV aGvHD, including two with grade III–IV aGvHD. Six patients experienced chronic GvHD, among whom four were mild and two were moderate. Twelve patients experienced infections during BMT. One was diagnosed with post-transplant lymphoproliferative disorder and one with probable EBV disease, and both recovered after rituximab infusion. Haplo-BMT achieved 3-year overall survival and disease-free survival rate of 86.4%±0.73% after a median follow-up of 42 months, indicating its effectiveness as a salvage therapy. These promising outcomes may support haplo-BMT as an alternative treatment strategy for patients with SAA-II lacking HLA-matched donors.
Key words： severe aplastic anemia    non-severe acquired aplastic anemia    haploidentical bone marrow transplantation    outcomes
收稿日期: 2020-01-22      出版日期: 2021-11-01
Corresponding Author(s): Yan Yang,Hengxiang Wang,Jinsong Yan   
 引用本文:   
. [J]. Frontiers of Medicine, 2021, 15(5): 718-727.
Hongchen Liu, Xiaoli Zheng, Chengtao Zhang, Jiajun Xie, Beibei Gao, Jing Shao, Yan Yang, Hengxiang Wang, Jinsong Yan. Outcomes of haploidentical bone marrow transplantation in patients with severe aplastic anemia-II that progressed from non-severe acquired aplastic anemia. Front. Med., 2021, 15(5): 718-727.
 链接本文:  
https://academic.hep.com.cn/fmd/CN/10.1007/s11684-020-0807-4
https://academic.hep.com.cn/fmd/CN/Y2021/V15/I5/718
No. Sex Age (year) Disease duration (year) ECOG Donor (donor/age (year)) Blood typing (donor/recipient) HLA matching aGvHD/cGvHD Serum ferritin (ng/mL) Survival
(month)		 Outcome
Prior to BMT Post BMT
1 M 15 8 3 Father/40 O/O 5/10 IV (GIT)/− 1001 1389 51 Alive
2 M 12 5.3 3 Father/38 B/A 5/10 I (GIT)/mild 7350 11 467 44 Alive
3 F 17 10 3 Father/53 B/O 5/10 II (GIT)/− 639 1832 42 Alive
4* M 17 4 2 Father/42 AB/AB 5/10 −/mild 893 1210 42 Alive
5 M 7 4.3 2 Father/28 O/O 5/10 −/− 512 958 40 Alive
6 M 35 22 2 Father/60 A/O 5/10 −/mild 3931 5190 37 Alive
7** M 26 21 3 Mother/49 B/O 5/10 3848 0 Death
8 M 21 16 3 Mother/47 O/O 5/10 I (skin)/moderate 5437 4586 34 Alive
9 M 13 11 3 Father/42 A/A 5/10 −/− 2227 2537 15 Death
10 F 22 4.5 3 Father/45 B/B 5/10 −/− 6666 1591 28 Alive
11 F 11 8 2 Father/38 O/O 5/10 −/− 1793 1800 55 Alive
12 F 5 2 2 Father/30 A/A 5/10 −/− 3578 4300 54 Alive
13 F 9 4 2 Father/34 AB/A 5/10 −/moderate 9559 8921 55 Alive
14 M 26 11.3 3 Mother/48 AB/A 5/10 I (skin)/− 7458 9233 53 Alive
15 M 16 1 2 Father/47 O/O 5/10 −/− 2669 2100 51 Alive
16 M 25 1.4 2 Sister/34 O/O 5/10 −/mild 2763 3202 51 Alive
17 M 15 1.2 2 Father/42 O/B 5/10 −/− 941 801 51 Alive
18 F 14 7 3 Father/43 A/A 5/10 II (Skin)/− 1738 1356 50 Alive
19 F 26 8 2 Father/49 O/B 5/10 −/− 5824 6320 43 Alive
20 F 27 13 3 Brother/22 A/O 5/10 −/− 2148 2254 39 Alive
21 M 19 10 3 Mother/43 O/O 5/10 III (GIT)/− 2821 3838 30 Alive
22 F 28 15 2 Brother/32 O/O 5/10 −/− 2632 22 714 10 Death
Tab.1  
Before transplantation 30 days 60 days 90 days
Cells (×106/L), median (range)
Total lymphocytes 1092 (432–2604) 190 (31–523) 1036 (276–2806) 1183 (172–1984)
CD3+ 905 (410–2211) 85 (4–130) 864 (88–1729) 846 (49–1885)
CD4+ 343 (164–1318) 7 (0–47) 104 (10–200) 53 (16–309)
CD8+ 392 (183–956) 44 (2–73) 718 (72–1257) 502 (24–1504)
Natural killer 99 (3–434) 94 (22–345) 247 (29–612) 182 (61–540)
CD19+ 117 (19–241) 17 (2–58) 12 (0–374) 14 (1–260)
Immunoglobulin (g/L), median (range)
IgA 1.97 (1.26–2.90) 0.77 (0.47–0.89) 0.39 (0.25–0.92) 0.3 (0.23–1.15)
IgG 10.7 (7.74–17.7) 14.6 (13.3–16.4) 13.1 (7.34–20.4) 17.9 (0.97–20.1)
IgM 1.02 (0.61–2.17) 0.46 (0.31–0.83) 0.31 (0.19–0.31) 0.59 (0.16–23.8)
180 days 365 days 730 days
Cells (×106/L), median (range)
Total lymphocytes 1153 (837–1832) 983(772–2666) 1465(1405–2259)
CD3+ 714 (402–1239) 800 (679–1868) 1029 (948–1665)
CD4+ 139 (37–222) 216 (134–551) 303 (285–533)
CD8+ 450 (265–1053) 516 (459–1026) 658 (522–979)
Natural killer 267 (29–711) 198 (35–269) 113 (70–345)
CD19+ 153 (13–738) 108 (50–641) 346 (131–456)
Immunoglobulin (g/L), median (range)
IgA 0.4 (0.26–0.89) 0.82 (0.25–2.88) 1.20 (1.08–1.7)
IgG 7.77 (2.8–19.8) 10.3 (3.08–19.3) 11.2 (7.83–12.6)
IgM 0.48 (0.18–0.7) 0.71 (0.42–1.41) 0.69 (0.5–1.39)
Tab.2  
Patient No. Cellularity (%) CD34+ CD42b CD61
Before After Before After Before After Before After
1 <10 60 – + – + – +
4 <10 20–30 – + – + – +
12 <10 40–50 – + – + – +
13 <10 30–40 – + – + – +
14 <10 40 – + – + – +
15 <10 30–40 – + – + – +
17 <10 40 – + – + – +
Tab.3  
Fig.1  
1 A Bacigalupo. How I treat acquired aplastic anemia. Blood 2017; 129(11): 1428–1436
https://doi.org/10.1182/blood-2016-08-693481 pmid: 28096088
2 NS Young. Pathophysiologic mechanisms in acquired aplastic anemia. Hematology American Society of Hematology Education Program 2006: 72–77
3 GE Georges, R Storb. Hematopoietic stem cell transplantation for acquired aplastic anemia. Curr Opin Hematol 2016; 23(6): 495–500
https://doi.org/10.1097/MOH.0000000000000281 pmid: 27607445
4 JP Li, CL Zheng, ZC Han. Abnormal immunity and stem/progenitor cells in acquired aplastic anemia. Crit Rev Oncol Hematol 2010; 75(2): 79–93
https://doi.org/10.1016/j.critrevonc.2009.12.001 pmid: 20045349
5 K Vaht, M Göransson, K Carlson, C Isaksson, S Lenhoff, A Sandstedt, B Uggla, J Winiarski, P Ljungman, M Brune, PO Andersson. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica 2017; 102(10): 1683–1690
https://doi.org/10.3324/haematol.2017.169862 pmid: 28751565
6 A Barone, A Lucarelli, D Onofrillo, F Verzegnassi, S Bonanomi, S Cesaro, F Fioredda, AP Iori, S Ladogana, A Locasciulli, D Longoni, M Lanciotti, A Macaluso, R Mandaglio, N Marra, B Martire, M Maruzzi, G Menna, LD Notarangelo, G Palazzi, M Pillon, U Ramenghi, G Russo, J Svahn, F Timeus, F Tucci, C Cugno, M Zecca, P Farruggia, C Dufour, P; SaraccoMarrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association. Diagnosis and management of acquired aplastic anemia in childhood. Blood Cells Mol Dis 2015; 55(1): 40–47
https://doi.org/10.1016/j.bcmd.2015.03.007 pmid: 25976466
7 E Montané, L Ibáñez, X Vidal, E Ballarín, R Puig, N García, JR Laporte; Catalan Group for Study of Agranulocytosis and Aplastic Anemia. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 2008; 93(4): 518–523
https://doi.org/10.3324/haematol.12020 pmid: 18322256
8 N Frickhofen, JP Kaltwasser, H Schrezenmeier, A Raghavachar, HG Vogt, F Herrmann, M Freund, P Meusers, A Salama, H Heimpel. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 1991; 324(19): 1297–1304
https://doi.org/10.1056/NEJM199105093241901 pmid: 2017225
9 SJ Rosenfeld, J Kimball, D Vining, NS Young. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995; 85(11): 3058–3065
https://doi.org/10.1182/blood.V85.11.3058.bloodjournal85113058 pmid: 7756640
10 N Kekre, Y Zhang, MJ Zhang, J Carreras, P Ahmed, P Anderlini, EH Atta, M Ayas, JJ Boelens, C Bonfim, HJ Deeg, N Kapoor, JW Lee, R Nakamura, MA Pulsipher, M Eapen, JH Antin. Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica 2017; 102(7): 1291–1298
https://doi.org/10.3324/haematol.2017.164459 pmid: 28341733
11 JH Kwon, I Kim, YG Lee, Y Koh, HC Park, EY Song, HK Kim, SS Yoon, DS Lee, SS Park, HY Shin, S Park, MH Park, HS Ahn, BK Kim. Clinical course of non-severe aplastic anemia in adults. Int J Hematol 2010; 91(5): 770–775
https://doi.org/10.1007/s12185-010-0601-1 pmid: 20524094
12 N Nishio, H Yagasaki, Y Takahashi, H Muramatsu, A Hama, N Yoshida, K Kudo, S Kojima. Natural history of transfusion-independent non-severe aplastic anemia in children. Int J Hematol 2009; 89(4): 409–413
https://doi.org/10.1007/s12185-009-0302-9 pmid: 19343478
13 S Wang, Y Chen, Y Zou, Y Zheng, X Zhu. The progression risk factors of children with transfusion-independent non-severe aplastic anemia. Int J Hematol 2013; 97(2): 210–215
https://doi.org/10.1007/s12185-013-1263-6 pmid: 23361447
14 SC Howard, PE Naidu, XJ Hu, MR Jeng, C Rodriguez-Galindo, MD Rieman, WC Wang. Natural history of moderate aplastic anemia in children. Pediatr Blood Cancer 2004; 43(5): 545–551
https://doi.org/10.1002/pbc.20131 pmid: 15382271
15 DM Townsley, P Scheinberg, T Winkler, R Desmond, B Dumitriu, O Rios, B Weinstein, J Valdez, J Lotter, X Feng, M Desierto, H Leuva, M Bevans, C Wu, A Larochelle, KR Calvo, CE Dunbar, NS Young. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med 2017; 376(16): 1540–1550
https://doi.org/10.1056/NEJMoa1613878 pmid: 28423296
16 LP Xu, XH Zhang, FR Wang, XD Mo, TT Han, W Han, YH Chen, YY Zhang, JZ Wang, CH Yan, YQ Sun, SN Zuo, XJ Huang. Haploidentical transplantation for pediatric patients with acquired severe aplastic anemia. Bone Marrow Transplant 2017; 52(3): 381–387
https://doi.org/10.1038/bmt.2016.281 pmid: 27941773
17 BM Camitta. Pathogenesis and treatment of aplastic anemia. Rinsho Ketsueki 1984; 25(4): 459–469
pmid: 6381789
18 A Tefferi, HK Al-Ali, G Barosi, T Devos, H Gisslinger, Q Jiang, JJ Kiladjian, R Mesa, F Passamonti, MF McMullin, V Ribrag, G Schiller, AM Vannucchi, D Zhou, D Reiser, J Zhong, RP Gale. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia 2017; 31(4): 896–902
https://doi.org/10.1038/leu.2016.300 pmid: 27773929
19 RP Gale, G Barosi, T Barbui, F Cervantes, K Dohner, B Dupriez, V Gupta, C Harrison, R Hoffman, JJ Kiladjian, R Mesa, MF Mc Mullin, F Passamonti, V Ribrag, G Roboz, G Saglio, A Vannucchi, S Verstovsek. What are RBC-transfusion-dependence and-independence? Leuk Res 2011; 35(1): 8–11
https://doi.org/10.1016/j.leukres.2010.07.015 pmid: 20692036
20 A Waszczuk-Gajda, K Mądry, R Machowicz, J Drozd-Sokołowska, B Stella-Hołowiecka, A Mital, A Obara, A Szmigielska-Kapłon, A Sikorska, E Subocz, WW Jędrzejczak, J Dwilewicz-Trojaczek. Red blood cell transfusion dependency and hyperferritinemia are associated with impaired survival in patients diagnosed with myelodysplastic syndromes: results from the first Polish MDS-PALG Registry. Adv Clin Exp Med 2016; 25(4): 633–641
https://doi.org/10.17219/acem/62397 pmid: 27629836
21 AC Harris, R Young, S Devine, WJ Hogan, F Ayuk, U Bunworasate, C Chanswangphuwana, YA Efebera, E Holler, M Litzow, R Ordemann, M Qayed, AS Renteria, R Reshef, M Wölfl, YB Chen, S Goldstein, M Jagasia, F Locatelli, S Mielke, D Porter, T Schechter, Z Shekhovtsova, JL Ferrara, JE Levine. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 2016; 22(1): 4–10
https://doi.org/10.1016/j.bbmt.2015.09.001 pmid: 26386318
22 MH Jagasia, HT Greinix, M Arora, KM Williams, D Wolff, EW Cowen, J Palmer, D Weisdorf, NS Treister, GS Cheng, H Kerr, P Stratton, RF Duarte, GB McDonald, Y Inamoto, A Vigorito, S Arai, MB Datiles, D Jacobsohn, T Heller, CL Kitko, SA Mitchell, PJ Martin, H Shulman, RS Wu, CS Cutler, GB Vogelsang, SJ Lee, SZ Pavletic, ME Flowers. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21(3): 389–401.e1
https://doi.org/10.1016/j.bbmt.2014.12.001 pmid: 25529383)
23 JW van Esser, B van der Holt, E Meijer, HG Niesters, R Trenschel, SF Thijsen, AM van Loon, F Frassoni, A Bacigalupo, UW Schaefer, AD Osterhaus, JW Gratama, B Löwenberg, LF Verdonck, JJ Cornelissen. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT. Blood 2001; 98(4): 972–978
https://doi.org/10.1182/blood.V98.4.972 pmid: 11493441
24 P Ljungman, M Boeckh, HH Hirsch, F Josephson, J Lundgren, G Nichols, A Pikis, RR Razonable, V Miller, PD; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum Griffiths. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 2017; 64(1): 87–91
https://doi.org/10.1093/cid/ciw668 pmid: 27682069
25 AN Miller, A Glode, KR Hogan, C Schaub, C Kramer, RK Stuart, LJ Costa. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17(8): 1176–1181
https://doi.org/10.1016/j.bbmt.2010.12.700 pmid: 21185389
26 SB Han, EY Bae, JW Lee, PS Jang, DG Lee, NG Chung, DC Jeong, B Cho, SJ Lee, JH Kang, HK Kim. Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus. Int J Hematol 2014; 100(2): 188–199
https://doi.org/10.1007/s12185-014-1613-z pmid: 24981711
27 HG Niesters, J van Esser, E Fries, KC Wolthers, J Cornelissen, AD Osterhaus. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000; 38(2): 712–715
https://doi.org/10.1128/JCM.38.2.712-715.2000 pmid: 10655372
28 JW van Esser, HG Niesters, B van der Holt, E Meijer, AD Osterhaus, JW Gratama, LF Verdonck, B Löwenberg, JJ Cornelissen. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99(12): 4364–4369
https://doi.org/10.1182/blood.V99.12.4364 pmid: 12036863
29 DM Knowles, E Cesarman, A Chadburn, G Frizzera, J Chen, EA Rose, RE Michler. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85(2): 552–565
https://doi.org/10.1182/blood.V85.2.552.552 pmid: 7812011
30 J Styczynski, P Reusser, H Einsele, R de la Camara, C Cordonnier, KN Ward, P Ljungman, D Engelhard; Second European Conference on Infections in Leukemia. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43(10): 757–770
https://doi.org/10.1038/bmt.2008.386 pmid: 19043458
31 J Sanz, R Andreu. Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation. Curr Opin Oncol 2014; 26(6): 677–683
https://doi.org/10.1097/CCO.0000000000000119 pmid: 25162331
32 M Boeckh, P Ljungman. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113(23): 5711–5719
https://doi.org/10.1182/blood-2008-10-143560 pmid: 19299333
33 F El Chaer, DP Shah, RF Chemaly. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood 2016; 128(23): 2624–2636
https://doi.org/10.1182/blood-2016-06-688432 pmid: 27760756
34 C Harkensee, N Vasdev, AR Gennery, IE Willetts, C Taylor. Prevention and management of BK-virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation—a systematic review and evidence-based guidance for clinical management. Br J Haematol 2008; 142(5): 717–731
https://doi.org/10.1111/j.1365-2141.2008.07254.x pmid: 18540939
35 LP Xu, SQ Wang, DP Wu, JM Wang, SJ Gao, M Jiang, CB Wang, X Zhang, QF Liu, LH Xia, X Wang, XJ Huang. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. Br J Haematol 2016; 175(2): 265–274
https://doi.org/10.1111/bjh.14225 pmid: 27352174
36 S Pagliuca, R Peffault de Latour, F Volt, F Locatelli, M Zecca, JH Dalle, P Comoli, K Vettenranta, MA Diaz, O Reuven, Y Bertrand, C Diaz de Heredia, A Nagler, A Ghavamzadeh, S Sufliarska, S Lawson, C Kenzey, V Rocha, C Dufour, E Gluckman, J Passweg, A Ruggeri. Long-term outcomes of cord blood transplantation from an HLA-identical sibling for patients with bone marrow failure syndromes: a report from Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2017; 23(11): 1939–1948
https://doi.org/10.1016/j.bbmt.2017.08.004 pmid: 28797779
37 M Döring, C Müller, PD Johann, A Erbacher, A Kimmig, CP Schwarze, P Lang, R Handgretinger, I Müller. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis 2012; 12(1): 263
https://doi.org/10.1186/1471-2334-12-263 pmid: 23082876
38 XJ Huang, DH Liu, KY Liu, LP Xu, H Chen, W Han, YH Chen, XH Zhang, DP Lu. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15(2): 257–265
https://doi.org/DOI: 10.1016/j.bbmt.2008.11.025 pmid: 19167686
39 L Xu, Z Liu, Y Wu, X Yang, Y Cao, X Li, B Yan, S Li, W Da, X Wu. Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia. Eur J Med Res 2018; 23(1): 12
https://doi.org/10.1186/s40001-018-0311-3 pmid: 29490698
40 LP Xu, S Jin, SQ Wang, LH Xia, H Bai, SJ Gao, QF Liu, JM Wang, X Wang, M Jiang, X Zhang, DP Wu, XJ Huang. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol 2017; 10(1): 25
https://doi.org/10.1186/s13045-017-0398-y pmid: 28107815
41 Y Zeng, S Wang, J Wang, L Liu, Y Su, Z Lu, X Zhang, Y Zhang, JF Zhong, L Peng, Q Liu, Y Lu, L Gao, X Zhang. Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: a large-sample study from China. Sci Rep 2018; 8(1): 2479
https://doi.org/10.1038/s41598-018-20853-9 pmid: 29410500
42 K Kataoka, Y Nannya, A Hangaishi, Y Imai, S Chiba, T Takahashi, M Kurokawa. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15(2): 195–204
https://doi.org/10.1016/j.bbmt.2008.11.012 pmid: 19167679
43 Y Cheng, Z Xu, Y Zhang, J Wu, F Wang, X Mo, Y Chen, W Han, J Jia, Y Wang, X Zhang, X Huang, L Zhang, L Xu. First-line choice for severe aplastic anemia in children: transplantation from a haploidentical donor vs immunosuppressive therapy. Clin Transplant 2018; 32(2): e13179
https://doi.org/10.1111/ctr.13179 pmid: 29297952
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed